Metabolic susceptibility to agricultural pesticides and non-Hodgkin's lymphoma

Scandinavian Journal of Work, Environment and Health

Volumn 31, Issue SUPPL. 1, 2005, Pages 26-32

  Schroeder, Jane C ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

Butyrylcholinesterase; Cytochrome P 450; Gene environment interaction; Glucuronosyltransferase; Glutathione S transferase; Paraoxonase; Polymorphism; Review; Sulfotransferase

Indexed keywords

AGRICULTURAL CHEMICAL; ARYLDIALKYLPHOSPHATASE; CHOLINESTERASE; CYTOCHROME P450 1A1; GLUTATHIONE TRANSFERASE; ORGANOPHOSPHATE; PESTICIDE;

AGRICULTURAL WORKER; CANCER; METABOLISM; PESTICIDE;

DETOXIFICATION; DNA POLYMORPHISM; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGICAL DATA; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLUTATHIONE METABOLISM; HUMAN; LYMPHOCYTE; METABOLIC PARAMETERS; METABOLITE; NONHODGKIN LYMPHOMA; OCCUPATIONAL CANCER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROLYSIS; LYMPHOMA, NON-HODGKIN; METABOLIC DETOXICATION, DRUG; OCCUPATIONAL EXPOSURE; PESTICIDES;

EID: 24944454304     PISSN: 03553140     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Khuder SA, Schaub EA, Keller-Byrne JE. Meta-analyses of non-Hodgkin's lymphoma and farming. Scand J Work Environ Health 1998;24(4):255-61.
2. Zahm S, Blair A. Pesticides and non-Hodgkin's lymphoma. Cancer Res 1992;52s:5485s-8s.
3. Pearce N, Reif J. Epidemiologic studies of cancer in agricultural workers. Am J Ind Med 1990;18:133-48.
4. Blair A, Hoar Zahm S, Pearce N, Heineman EF, Fraumeni JF Jr. Clues to cancer etiology from studies of farmers [review]. Scand J Work Environ Health 1992;18:209-15.
5. Magrath I. Molecular basis of lymphomagenesis. Cancer Res 1992;52s:5529s.
6. Herrinton L. Epidemiology of the revised European-American lymphoma classification subtypes. Epidemiol Rev 1998;20:187-203.
7. Groves FD, Liner MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92(15):1240-51.
8. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002;156(4):300-10.
9. Vineis P, Martone T. Genetic-environmental interactions and low-level exposure to carcinogens. Epidemiology 1995; 6(4):455-7.
10. Hirvonen A. Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer. Environ Health Perspect 1999;107 suppl 1:37-47.
11. Lang DH, Rettie AE, Bocker RH. Identification of enzymes involved in the metabolism of atrazine, terbuthylazine, ametryne, and terbutryne in human liver microsomes. Chem Res Toxicol 1997;10(9):1037-44.
12. Spatzenegger M, Horsmans Y, Verbeeck RK. CYP1A1 but not CYP1A2 proteins are expressed in human lymphocytes. Pharmacol Toxicol 2000;86(5):242-4.
13. Delescluse C, Ledirac N, Li R, Piechocki MP, Hines RN, Gidrol X, et al. Induction of cytochrome P450 1A1 gene expression, oxidative stress, and genotoxicity by carbaryl and thiabendazole in transfected human HepG2 and lymphoblastoid cells. Biochem Pharmacol 2001;61(4):399-407.
14. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J Biochem (Tokyo) 1991;110(3):407-11.
15. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994;4(5):242-6.
16. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994;15(12):2961-3.
17. Persson I, Johansson I, Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 1997;231(1):227-30.
18. Kawajiri K. CYP1A1 In: Book AS, editor. Metabolic polymorphisms and susceptibility to cancer. Lyon: International Agency for Research on Cancer; 1999.
19. Sarmanova J, Benesova K, Gut I, Nedelcheva-Kristensen V, Tynkova L, Soucek P. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Hum Mol Genet 2001;10(12):1265-73.
20. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 2002; 118(2):477-81.
21. Infante-Rivard C, Labuda D, Krajinovic M, Sinnett D. Risk of childhood leukemia associated with exposure to pesticides and with gene polymorphisms. Epidemiology 1999;10(5):481-7.
22. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1 CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999;93(5):1496-501.
23. Raunio H, Hakkola J, Hukkanen J, Pelkonen O, Edwards R, Boobis A, et al. Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. Arch Toxicol Suppl 1998;20:465-9.
24. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, et al. Sequence analysis and homology modelling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 1998;62(3):573-84.
25. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002;61(3):586-94.
26. Tang J, Cao Y, Rose RL, Hodgson E. In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos. Chem Biol Interact 2002;141(3):229-41.
27. Mutch E, Blain PG, Williams FM. The role of metabolism in determining susceptibility to parathion toxicity in man. Toxicol Lett 1999;107(1-3):177-87.
28. Hu Y, Kupfer D. Metabolism of the endocrine disruptor pesticide-methoxychlor by human P450s: pathways involving a novel catechol metabolite. Drug Metab Dispos 2002;30(9):1035-42.
29. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002;12(2):121-32.
30. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 1999;125(4):803-8.
31. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C-A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47(4):445-9.
32. Landi M, Sinha R, Lang N, Kadlubar F. Human cytochrome P4501A2. In: Book AS, editor. Metabolic polymorphisms and susceptibility to cancer. Lyon: International Agency for Research on Cancer; 1999.
33. Sogorb MA, Vilanova E. Enzymes involved in the detoxification of organophosphorus, carbamate and pyrethroid insecticides through hydrolysis. Toxicol Lett 2002;128(1-3):215-28.
34. Lockridge O, Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. Neurotoxicology. 2000;21(1-2):113-26.
35. Lee MJ, Waters HC 3rd. Inhibition of monocyte esterase activity by organophosphate insecticides. Blood 1977;50(5):947-51.
36. Newcombe D. Immune surveillance, organophosphorus exposure, and lymphomagenesis. Lancet 1992;339:539-41.
37. Li Q, Nagahara N, Takahashi H, Takeda K, Okumura K, Minami M. Organophosphorus pesticides markedly inhibit the activities of natural killer, cytotoxic T lymphocyte and lymphokine-activated killer: a proposed inhibiting mechanism via granzyme inhibition. Toxicology 2002;172(3):181-90.
38. Barta C, Sasvari-Szekely M, Devai A, Kovacs E, Staub M, Enyedi P. Analysis of mutations in the plasma cholinesterase gene of patients with a history of prolonged neuromuscular block during anesthesia. Mol Genet Metab 2001;74(4):484-8.
39. Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T, et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 1992;50(5):1086-103.
40. Maekawa M, Sudo K, Dey DC, Ishikawa J, Izumi M, Kotani K, et al. Genetic mutations of butyrylcholine esterase identified from phenotypic abnormalities in Japan. Clin Chem 1997;43(6 Pt 1):924-9.
41. Primo-Parmo SL, Bartels CF, Wiersema B, van der Spek AF, Innis JW, La Du BN. Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. Am J Hum Genet 1996;58(1):52-64.
42. Wiebusch H, Poirier J, Sevigny P, Schappert K. Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet 1999;104(2):158-63.
43. Hashim Y, Shepherd D, Wiltshire S, Holman RR, Levy JC, Clark A, et al. Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects. Diabetologia. 2001;44(12):2227-30.
44. Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact 1999;119-120:429-38.
45. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3(1):73-6.
46. Cherry N, Mackness M, Durrington P, Povey A, Dippnall M, Smith T, et al. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 2002; 359(9308):763-4.
47. Sozmen EY, Mackness B, Sozmen B, Durrington P, Girgin FK, Aslan L, et al. Effect of organophosphate intoxication on human serum paraoxonase. Hum Exp Toxicol 2002; 21(5):247-52.
48. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001;68(6):1428-36.
49. La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA. Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos 2001;29(4 Pt 2):566-9.
50. Eaton DL. Biotransformation enzyme polymorphism and pesticide susceptibility. Neurotoxicology 2000;21(1-2):101-11.
51. Lemos MC, Cabrita FJ, Silva HA, Vivan M, Placido F, Regateiro FJ. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999;20(7):1225-9.
52. Yuille M, Condie A, Hudson C, Kote-Jarai Z, Stone E, Eeles R, et al. Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood 2002;99(11):4216-8.
53. Chen CL, Liu Q, Pui CH, Rivera GK, Sandlund JT, Ribeiro R, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997;89(5):1701-7.
54. Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal SS, Srivastava SK, et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 1994;224(3):893-9.
55. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants: evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997;272(15):10004-12.
56. Coughtrie MW, Johnston LE. Interactions between dietary chemicals and human sulfotransferases- molecular mechanisms and clinical significance. Drug Metab Dispos 2001;29(4 Pt 2):522-8.
57. Glatt H, Boeing H, Engelke CE, Ma L, Kuhlow A, Pabel U, et al. Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat Res 2001;482(1-2):27-40.
58. Krieger R. Handbook of pesticide toxicology; vol 2. San Diego (CA): Academic Press; 2001.
59. Burchell B, Soars M, Monaghan G, Cassidy A, Smith D, Ethell B. Drug-mediated toxicity caused by genetic deficiency of UDP- glucuronosyltransferases. Toxicol Lett 2000;112-113:333-40.
60. Grancharov K, Naydenova Z, Lozeva S, Golovinsky E. Natural and synthetic inhibitors of UDP-glucuronosyltransferase. Pharmacol Ther 2001;89(2):171-86.
61. Garte S. Metabolic susceptibility genes as cancer risk factors: time for a reassessment? Cancer Epidemiol Biomarkers Prev 2001;10(12):1233-7.
62. Judson R, Stephens JC. Notes from the SNP vs. haplotype front. Pharmacogenomics 2001;2(1):7-10.
63. Pearce N. Analytical implications of epidemiological concepts of interaction. Int J Epidemiol 1989;18:976-80.
64. Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem 2001;276(43):39638-44.
65. Sinha R, Caporaso N. Diet, genetic susceptibility and human cancer etiology. J Nutr 1999;129(2S Suppl):556S-9S.
66. Faustman EM, Silbernagel SM, Fenske RA, Burbacher TM, Ponce RA. Mechanisms underlying children's susceptibility to environmental toxicants. Environ Health Perspect 2000;108 suppl 1:13-21.
67. Coumoul X, Diry M, Robillot C, Barouki R. Differential regulation of cytochrome P450 1A1 and 1B1 by a combination of dioxin and pesticides in the breast tumor cell line MCF-7. Cancer Res 2001;61(10):3942-8.
68. Kannan K, Holcombe RF, Jain SK, Alvarez-Hernandez X, Chervenak R, Wolf RE, et al. Evidence for the induction of apoptosis by endosulfan in a human T-cell leukemic line. Mol Cell Biochem 2000;205(1-2):53-66.
69. Banerjee BD, Seth V, Bhattacharya A, Pasha ST, Chakraborty AK. Biochemical effects of some pesticides on lipid peroxidation and free- radical scavengers. Toxicol Lett 1999;107(1-3):33-47.
70. Difilippantonio MJ, Zhu J, Chen HT, Meffre E, Nussenzweig MC, Max EE, et al. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 2000;404(6777):510-4.
71. Papavasiliou FN, Schatz DG. Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immumoglobulin genes. Nature 2000;408(6809):216-21.
72. Banerjee BD. The influence of various factors on immune toxicity assessment of pesticide chemicals. Toxicol Lett 1999;107(1-3):21-31.
73. Kristensen VN, Kure EH, Erikstein B, Harada N, Borresen-Dale A. Genetic susceptibility and environmental estrogen-like compounds. Mutat Res 2001;482(1-2):77-82.
74. Bell D, Liu Y, Cortopassi G. Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers. J Natl Cancer Inst 1995;87:223-4.
75. Fuscoe J, Setzer R, Collard D, Moore M. Quantification of t(14;18) in the lymphocytes of healthy adult humans as a possible biomarker for environmental exposures to carcinogens. Carcinogenesis 1996;17:1013-20.
76. Limpens J, Stad R, Vos C, Vlaam Cd, deJong D, Ommen GJBv, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995;85:2528.
77. Liu Y, Cortopassi G, Steingrimsdottir H, Waugh AP, Beare DM, Green MH, et al. Correlated mutagenesis of bcl2 and hprt loci in blood lymphocytes. Environ Mol Mutagen 1997;29(1):36-45.
78. Lander F, Knudsen LE, Gamborg MO, Järventaus H, Norppa H. Chromosome aberrations in pesticide-exposed greenhouse workers. Scand J Work Environ Health 2000;26(5):436-42.
79. Kiraly J, Szentesi I, Ruzicska M, Czeize A. Chromosome studies in workers producing organophosphate insecticides Arch Environ Contain Toxicol 1979;8:309-19.
80. Garry VF, Tarone RE, Long L, Griffith J, Kelly JT, Burroughs B. Pesticide appliers with mixed pesticide exposure: G-banded analysis and possible relationship to non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers 1996;5:11-16.
81. Norppa H. Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes. Environ Health Perspect 1997;105 suppl 4:829-35.
82. Weiss NS, Liff JM. Accounting for the multicausal nature of disease in the design and analysis of epidemiologic studies. Am J Epidemiol 1983;117(1):14-8.
83. Weisenburger D. Pathological classification of non-Hodgkin's lymphoma for epidemiological studies. Cancer Res 1992;52s:5456s.
84. McDuffie HH, Pahwa P, McLaughlin JR, Spinelli JJ, Fincham S, Dosman JA, et al. Non-Hodgkin's lymphoma and specific pesticide exposures in men: cross-Canada study of pesticides and health. Cancer Epidemiol Biomarkers Prev 2001;10(11):1155-63.
85. Cantor K, Blair A, Everett G, Gibson R, Burmeister L, Brown L, et al. Pesticides and other agricultural risk factors for non-Hodgkin's lymphoma among men in Iowa and Minnesota. Cancer Res 1992;52:2447.
86. Schroeder JC, Olshan AF, Baric R, Dent GA, Weinberg CR, Yount B, et al. Agricultural risk factors for t(14;18) subtypes of non-Hodgkin's lymphoma. Epidemiology 2001;12(6):701-9.
87. Schroeder JC, Olshan AF, Baric R, Dent RB, Weinberg CR, Yount B, et al. A case-control study of tobacco use and other non-occupational risk factors for t(14;18) subtypes of non-Hodgkin's lymphoma (United States). Cancer Causes Control 2002;13(2):159-68.
88. Williams JA. Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. Carcinogenesis 2001;22(2):209-14.
89. Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni JF Jr. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta 2001;2(10):C1-10.
90. Boffetta P, Pearce N. Epidemiological studies on genetic polymorphism: study design issues and measures of occurrence and association. In: Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzik J, et al, editors. Metabolic polymorphisms and susceptibility to cancer. Lyon: International Agency for Research on Cancer; 1999.
91. Greenland S. Can meta-analysis be salvaged? Am J Epidemiol 1994;140(9):783-7.
92. Elbaz A, Alperovitch A. Bias in association studies resulting from gene-environment interactions and competing risks. Am J Epidemiol 2002;155(3):265-72.
93. Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2000; 92(14):1151-8.